Patients hospitalized with mild COVID-19 in China exhibited a wide range of SARS-CoV-2-specific neutralizing antibodies, with a minority of patients with levels below the detectable limit of the assay, researchers found.
Out of 175 patients, 30% developed SARS-CoV-2-specific neutralizing antibody titers of less than 500, and 10 patients with neutralizing antibody titers under the detectable limit, reported Jinghe Huang, PhD, of Fudan University in Shanghai, and colleagues.
